Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTA
Previous Symbol
CUSIPN/A
Phone857-242-0170
Debt
Debt-to-Equity RatioN/A
Current Ratio13.66
Quick Ratio13.66
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees48
Outstanding Shares33,150,000
Market Cap$259.58 million
OptionableNot Optionable
Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions
What is Magenta Therapeutics' stock symbol?
Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."
How were Magenta Therapeutics' earnings last quarter?
Magenta Therapeutics Inc (NASDAQ:MGTA) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.18. View Magenta Therapeutics' Earnings History.
When is Magenta Therapeutics' next earnings date?
What price target have analysts set for MGTA?
4 analysts have issued twelve-month price targets for Magenta Therapeutics' shares. Their forecasts range from $18.00 to $22.00. On average, they expect Magenta Therapeutics' share price to reach $19.3333 in the next twelve months. This suggests a possible upside of 136.1% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.
What is the consensus analysts' recommendation for Magenta Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.
Has Magenta Therapeutics been receiving favorable news coverage?
Media stories about MGTA stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Magenta Therapeutics' key competitors?
Some companies that are related to Magenta Therapeutics include Amphastar Pharmaceuticals (AMPH), Apellis Pharmaceuticals (APLS), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB) and Lexicon Pharmaceuticals (LXRX).
Who are Magenta Therapeutics' key executives?
Magenta Therapeutics' management team includes the folowing people:
- Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 47)
- Mr. Michael P. Cooke, Chief Scientific Officer (Age 56)
- Ms. Alison Lawton, Board Advisor (Age 57)
- Ms. Cindy Driscoll, VP of Fin. & Treasurer (Age 52)
- Ms. Manisha Pai, VP of Investor Relations & Communications
When did Magenta Therapeutics IPO?
(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When does the company's lock-up period expire?
Magenta Therapeutics' lock-up period expires on Tuesday, December 18th. Magenta Therapeutics had issued 6,666,667 shares in its IPO on June 21st. The total size of the offering was $100,000,005 based on an initial share price of $15.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Who are Magenta Therapeutics' major shareholders?
Magenta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FIL Ltd (2.90%), Opaleye Management Inc. (2.19%), Laurion Capital Management LP (0.86%), BlackRock Inc. (0.52%), Vanguard Group Inc. (0.44%) and Platinum Investment Management Ltd. (0.22%). Company insiders that own Magenta Therapeutics stock include David Scadden and Jason Gardner. View Institutional Ownership Trends for Magenta Therapeutics.
Which institutional investors are selling Magenta Therapeutics stock?
Which institutional investors are buying Magenta Therapeutics stock?
MGTA stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., FIL Ltd, BlackRock Inc., Vanguard Group Inc., Bollard Group LLC and Platinum Investment Management Ltd.. Company insiders that have bought Magenta Therapeutics stock in the last two years include David Scadden and Jason Gardner. View Insider Buying and Selling for Magenta Therapeutics.
How do I buy shares of Magenta Therapeutics?
Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Magenta Therapeutics' stock price today?
One share of MGTA stock can currently be purchased for approximately $8.19.
How big of a company is Magenta Therapeutics?
Magenta Therapeutics has a market capitalization of $259.58 million. Magenta Therapeutics employs 48 workers across the globe.
What is Magenta Therapeutics' official website?
How can I contact Magenta Therapeutics?
Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]
MarketBeat Community Rating for Magenta Therapeutics (NASDAQ MGTA)
MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote "Outperform" if you believe MGTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
